Pipeline Report

The first quarter of 2026 marks a pivotal period for specialty pharmaceuticals, with several high-impact FDA approvals reshaping treatment paradigms and cost dynamics. Recent approvals include gene therapies such as WASKYRA (etuvetidigene autotemcel) for Wiskott-Aldrich syndrome and ITVISMA (onasemnogene abeparvovec-brve) for spinal muscular atrophy, both commanding multimillion-dollar one-time costs and expanding access to populations that previously had limited treatment options. Additionally, the FDA approval of oral WEGOVY (semaglutide) for obesity and cardiovascular risk reduction represents an alternative to injectable GLP-1 therapies that some may find more convenient. These launches signal clinical progress but also raise considerations around affordability and payer strategies given their high pricepoints and potential for rapid uptake.

Looking ahead, the pipeline features several agents with near-term FDA decisions that could further affect markets. Notable agents include RGX-121 (clemidsogene lanparvovec), a first-time gene therapy for Hunter syndrome, and KRESLADI (marnetegragene autotemcel) for leukocyte adhesion deficiency-I, both expected to secure approvals in early 2026 and priced in the multi-million-dollar range. In the weight management arena, orforglipron is poised to become the second oral GLP-1 agonist for obesity after oral WEGOVY. Oncology remains active with TAB-CEL (tabelecleucel) under FDA review for Epstein-Barr virus-positive post-transplant lymphoproliferative disease and a potential CAR T-cell expansion with YESCARTA (axicabtagene ciloleucel) for primary CNS lymphoma, reinforcing the trend toward highly targeted, high-cost therapies. Collectively, these developments underscore a continued shift toward precision medicine and therapies with curative intent, with implications for formulary management, value-based contracting, and long-term budget impact.

Alan R. Smith, MD
Vice President, Medical Director

Our quarterly publication is developed by our Clinical Pharmacy Drug Information team to provide additional drug pipeline information and insights to help health care leaders prepare for shifts in prescription drug management. Learn more by accessing the complete AcariaHealth January 2026 Pipeline Report (PDF).